Persistent dystonia and basal ganglia involvement following metronidazole induced encephalopathy
暂无分享,去创建一个
[1] F. Amin,et al. Metronidazole-induced encephalopathy: a systematic review , 2018, Journal of Neurology.
[2] Young Eun Kim,et al. Metronidazole-Induced Craniocervical Myoclonus with Reversible Bilateral Dentate Nucleus Lesions , 2017, Journal of movement disorders.
[3] S. Das,et al. Clinical and Neuroradiological Spectrum of Metronidazole Induced Encephalopathy: Our Experience and the Review of Literature. , 2016, Journal of clinical and diagnostic research : JCDR.
[4] Shigeaki Suzuki,et al. Metronidazole‐induced encephalopathy and myoclonus: Case report and a review of the literature , 2015 .
[5] N. Fischbein,et al. Metronidazole-Induced Encephalopathy: Not Always a Reversible Situation , 2015, Neurocritical Care.
[6] W. Tatum,et al. Nonconvulsive Status With Metronidazole , 2013, The Neurohospitalist.
[7] E. Mohammadi,et al. Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.
[8] A. Kuriyama,et al. Metronidazole-Induced Central Nervous System Toxicity: A Systematic Review , 2011, Clinical neuropharmacology.
[9] M. Miranda,et al. Movement disorders as a manifestation of metronidazole‐induced encephalopathy in a patient with chronic liver disease , 2009, Movement disorders : official journal of the Movement Disorder Society.
[10] J. Ferro,et al. Reversible iatrogenic subacute cerebellar syndrome, myoclonus and MRI findings following metronidazole administration , 2009, BMJ Case Reports.
[11] J. Meulenbelt,et al. Irreversible encephalopathy after treatment with high-dose intravenous metronidazole. , 2010, Clinical therapeutics.